Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
taxane + trastuzumab + pertuzumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination regimen consisting of a taxane (such as docetaxel or paclitaxel), trastuzumab, and pertuzumab. It is primarily used as first-line therapy for HER2-positive breast cancer, including both early-stage and metastatic settings. Taxanes are antimicrotubule agents that inhibit cell division by stabilizing microtubules, leading to cancer cell death. Trastuzumab and pertuzumab are monoclonal antibodies targeting the human epidermal growth factor receptor 2 (HER2). Trastuzumab binds to subdomain IV of HER2, while pertuzumab binds to subdomain II; together they provide dual blockade of HER2 signaling pathways, resulting in synergistic antitumor activity. This combination has demonstrated improved progression-free survival and overall survival compared to regimens without dual anti-HER2 therapy[1][3][4].
- Brand names
- HerceptinPerjetaTaxolAbraxaneTaxotere
- Other names
- THP chemoHP plus taxanetrastuzumab + pertuzumab + taxane
02
Targets
TUBB (Tubulin (alpha and beta subunits))HER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)
Beyond the preview
Go deeper on taxane + trastuzumab + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on taxane + trastuzumab + pertuzumab.